COLUMVI

all catalysts(0)

nothing on the calendar yet

News(6)

• Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
  Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…
  biospace · 2d ago
• ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
  When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
  fiercebiotech · 6d ago
• Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
  Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
  biospace · 9d ago
• Roche bets up to $1B to advance next-gen bispecifics with Dualitas
  The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
  biospace · 17d ago
• Roche, Dualitas team up to find bispecific drugs for immune diseases
  Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
  biopharma_dive · 17d ago
• Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
  Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
  fiercebiotech · 17d ago